Anticholinergic drugs for parkinsonism and other movement disorders
- PMID: 38904792
- DOI: 10.1007/s00702-024-02799-7
Anticholinergic drugs for parkinsonism and other movement disorders
Abstract
Anticholinergic (AC) drugs, a medication class that acts by blocking nicotinic and muscarinic acetylcholine receptors, were first utilized for therapeutic purposes in the mid-19th century. Initial applications were as symptomatic therapy for Parkinson disease (PD), a practice continuing to the present. Initially, the AC drugs used were naturally-occurring plant compounds. Synthetic AC drugs were developed in the late 1940s and predominated in neurological therapeutics. Until the advent of pharmaceuticals acting upon striatal dopaminergic motor pathways, AC drugs provided the only effective means for lessening tremors and other clinical problems of the PD patient. However, because dopaminergic compounds are so effective at meeting the needs of the typical PD patient, AC medications are far less utilized by clinicians today. In recent years, there has been only a few investigations of AC drugs as neurological treatments. This review will revisit the clinical landscape of AC pharmacology and application for movement disorders along with recent research in search of improving therapeutics with AC drugs.
Keywords: Acetylcholine; Anticholinergic; Dystonia; Movement disorders; Parkinson disease.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.
Similar articles
-
Chapter 33: the history of movement disorders.Handb Clin Neurol. 2010;95:501-46. doi: 10.1016/S0072-9752(08)02133-7. Handb Clin Neurol. 2010. PMID: 19892136 Review.
-
Mechanisms of Antiparkinsonian Anticholinergic Therapy Revisited.Neuroscience. 2021 Jul 15;467:201-217. doi: 10.1016/j.neuroscience.2021.05.026. Epub 2021 May 25. Neuroscience. 2021. PMID: 34048797 Review.
-
Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders.Nicotine Tob Res. 2019 Feb 18;21(3):357-369. doi: 10.1093/ntr/nty063. Nicotine Tob Res. 2019. PMID: 30137517 Free PMC article. Review.
-
Contribution of cholinergic interneurons to striatal pathophysiology in Parkinson's disease.Neurochem Int. 2019 Jun;126:1-10. doi: 10.1016/j.neuint.2019.02.019. Epub 2019 Feb 27. Neurochem Int. 2019. PMID: 30825602 Review.
-
Roles of the M4 acetylcholine receptor in the basal ganglia and the treatment of movement disorders.Mov Disord. 2019 Aug;34(8):1089-1099. doi: 10.1002/mds.27740. Epub 2019 Jun 18. Mov Disord. 2019. PMID: 31211471 Free PMC article. Review.
References
-
- Agate FJ Jr, Doshay LJ, Curtis FK (1956) Quantitative measurement of therapy in paralysis agitans. JAMA 160:352–354 - DOI
-
- Anderson E, Nutt J (2011) The long-duration response to levodopa: phenomenology, potential mechanisms, and clinical implications. Parkinsonism Relat Disord 7:589–592
-
- Ayd FJ (1961) A survey of drug-induced extrapyramidal reactions. JAMA 175:–1060
-
- Bergman H, Soares-Weiser K (2018) Anticholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev 17(1):CD000204
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical